Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database

INTRODUCTION: Treatment options in patients with mantle cell lymphoma (MCL) failing ibrutinib are limited, with no standard therapies defined. This study aimed to investigate real-world treatment patterns and outcomes for patients with MCL following ibrutinib. METHODS: This study utilized a de-ident...

Descripción completa

Detalles Bibliográficos
Autores principales: Rai, Shinya, Tanizawa, Yoshinori, Cai, Zhihong, Huang, Yu-Jing, Taipale, Kaisa, Tajimi, Masaomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464745/
https://www.ncbi.nlm.nih.gov/pubmed/35984628
http://dx.doi.org/10.1007/s12325-022-02258-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464745/
https://www.ncbi.nlm.nih.gov/pubmed/35984628
http://dx.doi.org/10.1007/s12325-022-02258-3

Ejemplares similares